A definitive and timely genetic diagnosis of PML::RARA fusion is critical for ATRA treatment and systemic therapy regimen decisions with inclusion of arsenic trioxide and/or chemotherapy in APL patients. This evidence concerns the gene PML and acute promyelocytic leukemia.